Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
This report contains market size and forecasts of Viral Vectors Gene Therapy in Global, including the following market information:
Global Viral Vectors Gene Therapy Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Viral Vectors Gene Therapy market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Retro Viral Vectors Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Viral Vectors Gene Therapy include Amgen, Novartis, Orchard Therapeutics, Spark Therapeutics, Agc Biologics, Anges, Bluebird Bio, Jazz Pharmaceuticals and Dynavax Technologies, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Viral Vectors Gene Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Viral Vectors Gene Therapy Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Viral Vectors Gene Therapy Market Segment Percentages, by Type, 2022 (%)
Retro Viral Vectors
Adeno-associated Virus Vectors
Other Viral Vectors
Global Viral Vectors Gene Therapy Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Viral Vectors Gene Therapy Market Segment Percentages, by Application, 2022 (%)
In Vivo
Ex Vivo
Global Viral Vectors Gene Therapy Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Viral Vectors Gene Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Viral Vectors Gene Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Viral Vectors Gene Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Biogen
Sarepta Therapeutics
Gilead Sciences
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Viral Vectors Gene Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Viral Vectors Gene Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Viral Vectors Gene Therapy Overall Market Size
2.1 Global Viral Vectors Gene Therapy Market Size: 2022 VS 2030
2.2 Global Viral Vectors Gene Therapy Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Viral Vectors Gene Therapy Players in Global Market
3.2 Top Global Viral Vectors Gene Therapy Companies Ranked by Revenue
3.3 Global Viral Vectors Gene Therapy Revenue by Companies
3.4 Top 3 and Top 5 Viral Vectors Gene Therapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Viral Vectors Gene Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Viral Vectors Gene Therapy Players in Global Market
3.6.1 List of Global Tier 1 Viral Vectors Gene Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Viral Vectors Gene Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Viral Vectors Gene Therapy Market Size Markets, 2022 & 2030
4.1.2 Retro Viral Vectors
4.1.3 Adeno-associated Virus Vectors
4.1.4 Other Viral Vectors
4.2 By Type - Global Viral Vectors Gene Therapy Revenue & Forecasts
4.2.1 By Type - Global Viral Vectors Gene Therapy Revenue, 2018-2023
4.2.2 By Type - Global Viral Vectors Gene Therapy Revenue, 2023-2030
4.2.3 By Type - Global Viral Vectors Gene Therapy Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Viral Vectors Gene Therapy Market Size, 2022 & 2030
5.1.2 In Vivo
5.1.3 Ex Vivo
5.2 By Application - Global Viral Vectors Gene Therapy Revenue & Forecasts
5.2.1 By Application - Global Viral Vectors Gene Therapy Revenue, 2018-2023
5.2.2 By Application - Global Viral Vectors Gene Therapy Revenue, 2023-2030
5.2.3 By Application - Global Viral Vectors Gene Therapy Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Viral Vectors Gene Therapy Market Size, 2022 & 2030
6.2 By Region - Global Viral Vectors Gene Therapy Revenue & Forecasts
6.2.1 By Region - Global Viral Vectors Gene Therapy Revenue, 2018-2023
6.2.2 By Region - Global Viral Vectors Gene Therapy Revenue, 2023-2030
6.2.3 By Region - Global Viral Vectors Gene Therapy Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Viral Vectors Gene Therapy Revenue, 2018-2030
6.3.2 US Viral Vectors Gene Therapy Market Size, 2018-2030
6.3.3 Canada Viral Vectors Gene Therapy Market Size, 2018-2030
6.3.4 Mexico Viral Vectors Gene Therapy Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Viral Vectors Gene Therapy Revenue, 2018-2030
6.4.2 Germany Viral Vectors Gene Therapy Market Size, 2018-2030
6.4.3 France Viral Vectors Gene Therapy Market Size, 2018-2030
6.4.4 U.K. Viral Vectors Gene Therapy Market Size, 2018-2030
6.4.5 Italy Viral Vectors Gene Therapy Market Size, 2018-2030
6.4.6 Russia Viral Vectors Gene Therapy Market Size, 2018-2030
6.4.7 Nordic Countries Viral Vectors Gene Therapy Market Size, 2018-2030
6.4.8 Benelux Viral Vectors Gene Therapy Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Viral Vectors Gene Therapy Revenue, 2018-2030
6.5.2 China Viral Vectors Gene Therapy Market Size, 2018-2030
6.5.3 Japan Viral Vectors Gene Therapy Market Size, 2018-2030
6.5.4 South Korea Viral Vectors Gene Therapy Market Size, 2018-2030
6.5.5 Southeast Asia Viral Vectors Gene Therapy Market Size, 2018-2030
6.5.6 India Viral Vectors Gene Therapy Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Viral Vectors Gene Therapy Revenue, 2018-2030
6.6.2 Brazil Viral Vectors Gene Therapy Market Size, 2018-2030
6.6.3 Argentina Viral Vectors Gene Therapy Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Viral Vectors Gene Therapy Revenue, 2018-2030
6.7.2 Turkey Viral Vectors Gene Therapy Market Size, 2018-2030
6.7.3 Israel Viral Vectors Gene Therapy Market Size, 2018-2030
6.7.4 Saudi Arabia Viral Vectors Gene Therapy Market Size, 2018-2030
6.7.5 UAE Viral Vectors Gene Therapy Market Size, 2018-2030
7 Players Profiles
7.1 Amgen
7.1.1 Amgen Corporate Summary
7.1.2 Amgen Business Overview
7.1.3 Amgen Viral Vectors Gene Therapy Major Product Offerings
7.1.4 Amgen Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.1.5 Amgen Key News
7.2 Novartis
7.2.1 Novartis Corporate Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Viral Vectors Gene Therapy Major Product Offerings
7.2.4 Novartis Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News
7.3 Orchard Therapeutics
7.3.1 Orchard Therapeutics Corporate Summary
7.3.2 Orchard Therapeutics Business Overview
7.3.3 Orchard Therapeutics Viral Vectors Gene Therapy Major Product Offerings
7.3.4 Orchard Therapeutics Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.3.5 Orchard Therapeutics Key News
7.4 Spark Therapeutics
7.4.1 Spark Therapeutics Corporate Summary
7.4.2 Spark Therapeutics Business Overview
7.4.3 Spark Therapeutics Viral Vectors Gene Therapy Major Product Offerings
7.4.4 Spark Therapeutics Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.4.5 Spark Therapeutics Key News
7.5 Agc Biologics
7.5.1 Agc Biologics Corporate Summary
7.5.2 Agc Biologics Business Overview
7.5.3 Agc Biologics Viral Vectors Gene Therapy Major Product Offerings
7.5.4 Agc Biologics Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.5.5 Agc Biologics Key News
7.6 Anges
7.6.1 Anges Corporate Summary
7.6.2 Anges Business Overview
7.6.3 Anges Viral Vectors Gene Therapy Major Product Offerings
7.6.4 Anges Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.6.5 Anges Key News
7.7 Bluebird Bio
7.7.1 Bluebird Bio Corporate Summary
7.7.2 Bluebird Bio Business Overview
7.7.3 Bluebird Bio Viral Vectors Gene Therapy Major Product Offerings
7.7.4 Bluebird Bio Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.7.5 Bluebird Bio Key News
7.8 Jazz Pharmaceuticals
7.8.1 Jazz Pharmaceuticals Corporate Summary
7.8.2 Jazz Pharmaceuticals Business Overview
7.8.3 Jazz Pharmaceuticals Viral Vectors Gene Therapy Major Product Offerings
7.8.4 Jazz Pharmaceuticals Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.8.5 Jazz Pharmaceuticals Key News
7.9 Dynavax Technologies
7.9.1 Dynavax Technologies Corporate Summary
7.9.2 Dynavax Technologies Business Overview
7.9.3 Dynavax Technologies Viral Vectors Gene Therapy Major Product Offerings
7.9.4 Dynavax Technologies Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.9.5 Dynavax Technologies Key News
7.10 Biogen
7.10.1 Biogen Corporate Summary
7.10.2 Biogen Business Overview
7.10.3 Biogen Viral Vectors Gene Therapy Major Product Offerings
7.10.4 Biogen Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.10.5 Biogen Key News
7.11 Sarepta Therapeutics
7.11.1 Sarepta Therapeutics Corporate Summary
7.11.2 Sarepta Therapeutics Business Overview
7.11.3 Sarepta Therapeutics Viral Vectors Gene Therapy Major Product Offerings
7.11.4 Sarepta Therapeutics Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.11.5 Sarepta Therapeutics Key News
7.12 Gilead Sciences
7.12.1 Gilead Sciences Corporate Summary
7.12.2 Gilead Sciences Business Overview
7.12.3 Gilead Sciences Viral Vectors Gene Therapy Major Product Offerings
7.12.4 Gilead Sciences Viral Vectors Gene Therapy Revenue in Global Market (2018-2023)
7.12.5 Gilead Sciences Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Viral Vectors Gene Therapy Market Opportunities & Trends in Global Market
Table 2. Viral Vectors Gene Therapy Market Drivers in Global Market
Table 3. Viral Vectors Gene Therapy Market Restraints in Global Market
Table 4. Key Players of Viral Vectors Gene Therapy in Global Market
Table 5. Top Viral Vectors Gene Therapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Viral Vectors Gene Therapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Viral Vectors Gene Therapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Viral Vectors Gene Therapy Product Type
Table 9. List of Global Tier 1 Viral Vectors Gene Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Viral Vectors Gene Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Viral Vectors Gene Therapy Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2023-2030
Table 14. By Application ? Global Viral Vectors Gene Therapy Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Viral Vectors Gene Therapy Revenue in Global (US$, Mn), 2023-2030
Table 17. By Region ? Global Viral Vectors Gene Therapy Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Viral Vectors Gene Therapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Viral Vectors Gene Therapy Revenue (US$, Mn), 2023-2030
Table 20. By Country - North America Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Viral Vectors Gene Therapy Revenue, (US$, Mn), 2023-2030
Table 22. By Country - Europe Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Viral Vectors Gene Therapy Revenue, (US$, Mn), 2023-2030
Table 24. By Region - Asia Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Viral Vectors Gene Therapy Revenue, (US$, Mn), 2023-2030
Table 26. By Country - South America Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Viral Vectors Gene Therapy Revenue, (US$, Mn), 2023-2030
Table 28. By Country - Middle East & Africa Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Viral Vectors Gene Therapy Revenue, (US$, Mn), 2023-2030
Table 30. Amgen Corporate Summary
Table 31. Amgen Viral Vectors Gene Therapy Product Offerings
Table 32. Amgen Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
Table 33. Novartis Corporate Summary
Table 34. Novartis Viral Vectors Gene Therapy Product Offerings
Table 35. Novartis Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
Table 36. Orchard Therapeutics Corporate Summary
Table 37. Orchard Therapeutics Viral Vectors Gene Therapy Product Offerings
Table 38. Orchard Therapeutics Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
Table 39. Spark Therapeutics Corporate Summary
Table 40. Spark Therapeutics Viral Vectors Gene Therapy Product Offerings
Table 41. Spark Therapeutics Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
Table 42. Agc Biologics Corporate Summary
Table 43. Agc Biologics Viral Vectors Gene Therapy Product Offerings
Table 44. Agc Biologics Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
Table 45. Anges Corporate Summary
Table 46. Anges Viral Vectors Gene Therapy Product Offerings
Table 47. Anges Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
Table 48. Bluebird Bio Corporate Summary
Table 49. Bluebird Bio Viral Vectors Gene Therapy Product Offerings
Table 50. Bluebird Bio Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
Table 51. Jazz Pharmaceuticals Corporate Summary
Table 52. Jazz Pharmaceuticals Viral Vectors Gene Therapy Product Offerings
Table 53. Jazz Pharmaceuticals Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
Table 54. Dynavax Technologies Corporate Summary
Table 55. Dynavax Technologies Viral Vectors Gene Therapy Product Offerings
Table 56. Dynavax Technologies Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
Table 57. Biogen Corporate Summary
Table 58. Biogen Viral Vectors Gene Therapy Product Offerings
Table 59. Biogen Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
Table 60. Sarepta Therapeutics Corporate Summary
Table 61. Sarepta Therapeutics Viral Vectors Gene Therapy Product Offerings
Table 62. Sarepta Therapeutics Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
Table 63. Gilead Sciences Corporate Summary
Table 64. Gilead Sciences Viral Vectors Gene Therapy Product Offerings
Table 65. Gilead Sciences Viral Vectors Gene Therapy Revenue (US$, Mn), (2018-2023)
List of Figures
Figure 1. Viral Vectors Gene Therapy Segment by Type in 2022
Figure 2. Viral Vectors Gene Therapy Segment by Application in 2022
Figure 3. Global Viral Vectors Gene Therapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Viral Vectors Gene Therapy Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Viral Vectors Gene Therapy Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Viral Vectors Gene Therapy Revenue in 2022
Figure 8. By Type - Global Viral Vectors Gene Therapy Revenue Market Share, 2018-2030
Figure 9. By Application - Global Viral Vectors Gene Therapy Revenue Market Share, 2018-2030
Figure 10. By Region - Global Viral Vectors Gene Therapy Revenue Market Share, 2018-2030
Figure 11. By Country - North America Viral Vectors Gene Therapy Revenue Market Share, 2018-2030
Figure 12. US Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 13. Canada Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 14. Mexico Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 15. By Country - Europe Viral Vectors Gene Therapy Revenue Market Share, 2018-2030
Figure 16. Germany Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 17. France Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 18. U.K. Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 19. Italy Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 20. Russia Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 21. Nordic Countries Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 22. Benelux Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 23. By Region - Asia Viral Vectors Gene Therapy Revenue Market Share, 2018-2030
Figure 24. China Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 25. Japan Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 26. South Korea Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 27. Southeast Asia Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 28. India Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 29. By Country - South America Viral Vectors Gene Therapy Revenue Market Share, 2018-2030
Figure 30. Brazil Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 31. Argentina Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 32. By Country - Middle East & Africa Viral Vectors Gene Therapy Revenue Market Share, 2018-2030
Figure 33. Turkey Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 34. Israel Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 35. Saudi Arabia Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 36. UAE Viral Vectors Gene Therapy Revenue, (US$, Mn), 2018-2030
Figure 37. Amgen Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 38. Novartis Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 39. Orchard Therapeutics Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 40. Spark Therapeutics Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 41. Agc Biologics Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Anges Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Bluebird Bio Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Jazz Pharmaceuticals Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Dynavax Technologies Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Biogen Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Sarepta Therapeutics Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Gilead Sciences Viral Vectors Gene Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
